Allena Pharmaceuticals
ALNA
ALNA was delisted on the 7th of September, 2022.
24 hedge funds and large institutions have $15.9M invested in Allena Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 10 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
20% less funds holding
Funds holding: 30 → 24 (-6)
25% less capital invested
Capital invested by funds: $21.2M → $15.9M (-$5.27M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$266K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$216K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$134K |
| 4 |
Goldman Sachs
New York
|
+$71.4K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.42M |
| 2 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$1.18M |
| 3 |
Renaissance Technologies
New York
|
-$975K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$128K |
| 5 |
Squarepoint
New York
|
-$81K |
ALNA Hedge Fund Activity: Q3 2020 in Review
24 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q3 2020, worth a combined $15.9M — down 25% from $21.2M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ALNA and 4 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $266K. The largest seller was Sabby Management, exiting entirely with an estimated $2.42M sold.
- 24 institutional investors held Allena Pharmaceuticals (ALNA) as of Q3 2020, down from 30 in Q2 2020.
- Funds reported $15.9M of Allena Pharmaceuticals stock for Q3 2020, down 25% quarter-over-quarter.
- 4 funds opened new Allena Pharmaceuticals positions in Q3 2020 and 10 closed out, a net change of -6 holders.
- The largest Allena Pharmaceuticals buyer in Q3 2020 was Qube Research & Technologies (QRT), an estimated $266K added.
- The largest Allena Pharmaceuticals seller in Q3 2020 was Sabby Management, an estimated $2.42M sold.
Based on aggregated 13F filings for Q3 2020.